LGALS3 and breast carcinoma: In particular, some studies show changes in the circulating levels of Gal-3 in response to treatment with cardiotoxic breast cancer therapies [37], without clear evidence of an association between elevated levels of Gal-3 and the incidence of cardiotoxicity [129].